Oncotelic Therapeutics Inc
oncotelic.comWhat Do They Do?
Develops antisense and injectable drug candidates for cancer treatment, alongside AI technologies for clinical development and manufacturing.
10-K for FY2025, filed Apr 15, 2026We are a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, developing antisense…View ↗
Developing newer AI based technologies to enhance the development and commercialization of support technologies. The JV has acquired a…View ↗
The Company is a clinical stage biopharmaceutical company developing drugs for the treatment of cancer. The Company’s proprietary product…View ↗
How Do They Make Money?
Customers pay for drug-development services as work is completed or over the service period; out-licensing payments are tied to milestones or required work.
10-K for FY2025, filed Apr 15, 2026The Company does not anticipate generating revenues from rendering services to other third party customers for the development of certain…View ↗
$70K
-
10-K for FY2024, filed Apr 15, 2025
$70K ↗
Do Revenues Turn Into Profits?
No. It lost $7.9M in FY2023.
10-K for FY2024, filed Apr 15, 2025
How Are They Changing?
-
May 5, 2026
Transfers intellectual property through a merger
Lunai issued Oncotelic preferred stock for its interest in the patent-holding entity; Oncotelic retained an exclusive license outside the biodefense and Alzheimer’s fields.
Sources
8-K, filed May 5, 2026
On April 27, 2026, Oncotelic Inc. (the “Company”), a wholly owned subsidiary of Oncotelic Therapeutics, Inc., entered into an Agreement and…View ↗
Shrinking. Revenue fell 96% in 3 years, from $1.7M in FY2020 to $70K in FY2023, about 66% a year.
Broader disease focus
The older report framed the pipeline around rare pediatric cancers; the latest describes a broader cancer program and plans to extend its RNA therapeutics work to Duchenne muscular dystrophy and other diseases.
10-K for FY2022, filed Apr 14, 2023 10-K for FY2025, filed Apr 15, 2026We are a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, developing antisense…View ↗
The Company is a clinical stage biopharmaceutical company developing drugs for the treatment of cancer. The Company’s proprietary product…View ↗
Loading...
